# IFNAR1: Type I Interferon Receptor Alpha Subunit, JAK-STAT Signal Transduction, and Antiviral Defense


## Key Takeaways

- IFNAR1 is the alpha subunit of the type I interferon receptor, essential for initiating JAK-STAT signaling upon binding of type I interferons (IFN-α, IFN-β, etc.) to the IFNAR1/IFNAR2 heterodimer. This cascade leads to the transcriptional upregulation of hundreds of interferon-stimulated genes (ISGs) critical for antiviral defense.
- The IFNAR1 gene is located on chromosome 21q22.11 and its promoter contains a microsatellite polymorphism (CA repeat) that has been correlated with interferon therapy responsiveness in hepatitis C patients, indicating direct impact on transcriptional output.
- Structural analysis reveals IFNAR1's extracellular domain comprises four fibronectin type III domains, forming a low-affinity ligand-binding site that, upon IFNAR2 engagement, facilitates receptor dimerization and JAK kinase activation.
- Germline loss-of-function mutations in IFNAR1, such as the Glu386* nonsense mutation, cause inborn errors of immunity leading to severe susceptibility to viral infections, including critical COVID-19 pneumonia and multisystem inflammatory syndrome in children (MIS-C).
- Viral pathogens like Feline calicivirus and African swine fever virus have evolved mechanisms to antagonize IFNAR1, either by degrading its mRNA or suppressing its signaling pathway, thereby evading host antiviral immunity.
- Anifrolumab, a monoclonal antibody targeting IFNAR1, is clinically approved for systemic lupus erythematosus, demonstrating the therapeutic potential of blocking type I interferon signaling in autoimmune diseases.

---

## Executive Summary & Key Metadata

The human **IFNAR1** gene encodes the alpha subunit of the type I interferon receptor (IFNAR), a critical transmembrane protein that forms a heterodimeric complex with IFNAR2 to mediate the biological activities of all type I interferons (IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω). This receptor complex is the primary conduit for innate antiviral immunity, orchestrating the JAK-STAT signaling cascade that culminates in the transcriptional upregulation of hundreds of interferon-stimulated genes (ISGs). Beyond its canonical antiviral functions, IFNAR1 signaling is implicated in immunomodulation, tumor surveillance, autoimmunity, and the pathogenesis of infectious diseases. The receptor's activity is tightly regulated at multiple levels, including transcriptional control, post-translational modifications (particularly ubiquitination and glycosylation), endocytic trafficking, and proteolytic cleavage. Genetic variants in IFNAR1 are associated with susceptibility to viral infections, autoimmune diseases, and certain malignancies, while therapeutic antibodies targeting IFNAR1 (e.g., anifrolumab) have entered clinical practice for systemic lupus erythematosus.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | IFNAR1 |
| UniProt Accession | P17181 |
| Representative PDB ID | 3SE3 |
| Chromosomal Locus | 21q22.11 |
| Primary Molecular Function | Type I interferon receptor subunit; cytokine receptor activity; JAK-STAT signal transduction |
| Disease & Pathology Associations | Severe viral infections (inborn errors of immunity), COVID-19 pneumonia, MIS-C, multiple sclerosis (treatment response), systemic lupus erythematosus (therapeutic target), breast cancer, hepatocellular carcinoma, tuberculosis, cerebral malaria, developmental stuttering |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The IFNAR1 gene is located on the long arm of human chromosome 21 at cytogenetic band **21q22.11**, a region of significant immunological interest due to its association with Down syndrome (trisomy 21) and its enrichment in interferon-related genes. The gene spans approximately 45 kilobases of genomic DNA on the plus strand, from approximately 34,260,000 to 34,305,000 bp (GRCh38/hg38 assembly). The genomic architecture includes 11 exons and 10 introns, with the translation initiation codon located in exon 2 and the termination codon in exon 11. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is entirely contained within exon 11.

The IFNAR1 locus is flanked by the IL10RB gene (encoding the [IL-10](/knowledge/bioinformatics/genes/immunology-checkpoints/il10-gene-structure-function-pathway) receptor beta subunit) on the centromeric side and the IFNGR2 gene (encoding the IFN-γ receptor 2) on the telomeric side. This genomic clustering of cytokine receptor genes on chromosome 21 suggests potential coordinated regulation and evolutionary conservation of immune-related gene families. A presumptive enhancer element has been identified in the intergenic region between IL10RB and IFNAR1, and structural variation in this region, including variable number tandem repeats (VNTRs), has been shown to exhibit post-zygotic and inter-individual variation, potentially influencing IFNAR1 expression levels.

### 1.2 Promoter Architecture and Transcriptional Regulation

The IFNAR1 promoter region lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for constitutive transcription factors including Sp1 and AP-2. The promoter is characterized by a dinucleotide microsatellite polymorphism, specifically a (CA) repeat, located approximately 1.4 kb upstream of the transcription start site. This microsatellite exhibits length polymorphism across individuals, and specific alleles have been correlated with responsiveness to interferon therapy in chronic hepatitis C patients, suggesting that promoter variation directly impacts IFNAR1 transcriptional output. The mechanistic basis for this association likely involves altered spacing between transcription factor binding sites or changes in chromatin structure that modulate promoter accessibility.

Transcriptional regulation of IFNAR1 is also influenced by upstream open reading frames (uORFs) in the 5' UTR, a feature shared with other immune receptors such as TNFR1. These uORFs can modulate translation efficiency in response to cellular stress and immune activation, providing a post-transcriptional layer of regulation that fine-tunes IFNAR1 protein abundance. The 3' UTR contains multiple microRNA binding sites, including a polymorphic miR-1231 binding site that has been associated with hepatocellular carcinoma susceptibility. This polymorphism (rs1051393) alters the affinity of miR-1231 for the IFNAR1 3' UTR, leading to differential post-transcriptional repression and consequent variation in IFNAR1 protein levels.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of IFNAR1 generates multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The predominant transcript encodes the full-length 557-amino acid protein. A soluble isoform, generated by alternative splicing that skips the transmembrane domain-encoding exons, has been detected in human serum and may function as a decoy receptor to sequester type I IFNs and modulate signaling intensity. Additional splice variants with deletions in the intracellular domain have been reported, which may exert dominant-negative effects on IFNAR signaling by competing with full-length IFNAR1 for heterodimerization with IFNAR2.

### 1.4 Cross-Species Conservation and Synteny

IFNAR1 is highly conserved across mammals, with orthologs identified in mouse (Ifnar1, chromosome 16), rat, pig, cattle, and sheep. The porcine IFNAR1 gene has been sequenced and characterized, revealing conserved intron-exon boundaries and a high degree of amino acid identity with the human protein. Notably, the mouse Ifnar1 gene is located on chromosome 16 in a region syntenic to human chromosome 21, and the Ts1Cje mouse model of Down syndrome carries a triplication of this region, resulting in overexpression of Ifnar1 in the brain. This overexpression has been linked to disrupted interferon-related molecular networks and cognitive impairment in this model, highlighting the dosage sensitivity of IFNAR1 signaling. The generation of Ifnar1 knockout mice, initially through conventional homologous recombination and more recently through CRISPR/Cas9-mediated genome editing, has provided essential tools for dissecting type I IFN biology in vivo. A novel Ifnar1 knockout mouse model generated by CRISPR/Cas9 with dual gRNAs has been described, demonstrating efficient gene disruption and confirming the utility of this approach for rapid generation of immunodeficient models.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The IFNAR1 protein (UniProt P17181) is a 557-amino acid type I transmembrane glycoprotein with a molecular weight of approximately 64.5 kDa (unglycosylated). The mature protein is heavily N-glycosylated, with a molecular weight of approximately 110-130 kDa as observed by SDS-PAGE. The protein is organized into three principal domains:

1. **Extracellular domain (ECD)**: Residues 1-436 (including the signal peptide, residues 1-28, which is cleaved during maturation). The mature ECD spans approximately residues 29-436 and contains four fibronectin type III (FNIII) domains, a structural motif characteristic of the class II cytokine receptor family. These FNIII domains are arranged in tandem and form a bent, elongated structure that provides the ligand-binding surface. The ECD contains 10 potential N-linked glycosylation sites (Asn-X-Ser/Thr motifs), and glycosylation is essential for proper protein folding, cell surface expression, and ligand binding.

2. **Transmembrane domain (TM)**: Residues 437-459. This single-pass alpha-helical domain anchors the receptor in the plasma membrane. The TM domain exhibits a conserved GxxxG dimerization motif that may facilitate homodimerization or heterodimerization with IFNAR2.

3. **Intracellular domain (ICD)**: Residues 460-557. This cytoplasmic region lacks intrinsic enzymatic activity but contains conserved motifs for association with Janus kinases (JAKs). The membrane-proximal region (residues 460-520) contains a Box1/Box2 motif that mediates constitutive association with TYK2 (tyrosine kinase 2). The distal region contains multiple tyrosine residues (Tyr466, Tyr481, Tyr527) that serve as phosphorylation sites and docking platforms for downstream signaling molecules such as STAT1, STAT2, and STAT3.

### 2.2 Three-Dimensional Structure

The three-dimensional structure of the IFNAR1 ECD has been determined by X-ray crystallography, with the representative structure deposited under PDB ID **3SE3**. This structure, solved at 3.0 Å resolution, reveals the ECD as an elongated, slightly curved rod-like structure approximately 120 Å in length. The four FNIII domains (designated D1-D4) are arranged in a nearly linear fashion, with each domain adopting the canonical beta-sandwich fold composed of two antiparallel beta-sheets. The domain-domain interfaces are stabilized by hydrophobic interactions and hydrogen bonds, creating a rigid, extended conformation.

The ligand-binding site is located primarily within domains D1 and D2, forming a shallow groove that accommodates the type I IFN ligands. Mutagenesis studies have identified key residues within this region, including Phe36, Trp102, and Leu130, that contribute to IFN-α binding affinity. The interaction between IFNAR1 and type I IFNs is characterized by relatively low affinity (Kd in the micromolar range for IFN-α2), which contrasts with the higher affinity binding of IFNs to IFNAR2 (Kd in the nanomolar range). This affinity asymmetry is functionally significant: IFNAR2 serves as the primary ligand-binding subunit, while IFNAR1 acts as a secondary, lower-affinity binding partner that is nonetheless essential for signal initiation. The low-affinity interaction between IFNAR1 and IFN-α2 has been exploited for therapeutic purposes, as engineered IFN-α2 mutants with enhanced IFNAR1 binding affinity exhibit increased antiproliferative and antiviral activities.

### 2.3 Structural Dynamics and Conformational Changes

The IFNAR1 ECD exhibits significant conformational plasticity that is critical for its function. Upon ligand binding to IFNAR2, the IFNAR1 ECD undergoes a conformational rearrangement that brings the transmembrane and intracellular domains of the two receptor subunits into close proximity. This ligand-induced dimerization is a prerequisite for JAK activation and downstream signaling. The structural basis for this conformational change has been inferred from studies of the related IFN-λ receptor complex and from hydrogen-deuterium exchange mass spectrometry analyses. The D1 domain of IFNAR1 is particularly dynamic, exhibiting conformational heterogeneity in solution that may facilitate initial low-affinity contacts with the ligand-IFNAR2 complex before stabilizing into a high-affinity signaling-competent conformation.

[Interactive 3D Protein Visualizer: Load IFNAR1 (PDB: 3SE3)](/tools/protein-structure-viewer?source=direct&pdbId=3SE3)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The JAK-STAT Signaling Cascade

The primary signaling pathway activated by IFNAR1 engagement is the JAK-STAT pathway, which transduces type I IFN signals from the cell surface to the nucleus. The signaling cascade is initiated when a type I IFN ligand (e.g., IFN-α or IFN-β) binds to the high-affinity IFNAR2 subunit, followed by recruitment of IFNAR1 to form a ternary signaling complex. This ligand-induced receptor clustering brings the constitutively associated JAK kinases into proximity: TYK2 is associated with IFNAR1, while JAK1 is associated with IFNAR2. The close apposition of TYK2 and JAK1 allows trans-phosphorylation and activation of both kinases.

Activated TYK2 and JAK1 then phosphorylate specific tyrosine residues on the intracellular domains of both receptor subunits. Phosphorylation of IFNAR1 at Tyr466 creates a docking site for the SH2 domain of STAT2, while phosphorylation of IFNAR2 at Tyr512 and Tyr517 recruits STAT1. The receptor-associated STAT proteins are themselves phosphorylated by the JAKs at conserved tyrosine residues (Tyr701 on STAT1, Tyr690 on STAT2). Phosphorylated STAT1 and STAT2 heterodimerize and associate with IRF9 (interferon regulatory factor 9) to form the transcription factor complex ISGF3 (interferon-stimulated gene factor 3). ISGF3 translocates to the nucleus and binds to interferon-stimulated response elements (ISREs) in the promoters of hundreds of ISGs, driving their transcriptional upregulation.

The ISGs induced by IFNAR1 signaling encode a diverse array of antiviral effectors, including Mx proteins (Mx1, Mx2), 2'-5'-oligoadenylate synthetase (OAS) family members, protein kinase R (PKR), [ISG15](/knowledge/bioinformatics/genes/virology-receptors/isg15-gene-structure-function-pathway), and viperin. These proteins collectively establish an antiviral state within the cell by targeting various stages of the viral life cycle, including viral entry, replication, translation, and assembly. The [Mx1 gene](/knowledge/bioinformatics/genes/virology-receptors/mx1-gene-structure-function-pathway), for example, is a well-characterized ISG whose expression is strictly dependent on type I IFN signaling through IFNAR1, making it a sensitive reporter of IFNAR pathway activation.

### 3.2 Non-Canonical Signaling Pathways

Beyond the canonical JAK-STAT pathway, IFNAR1 engagement activates several alternative signaling cascades that contribute to the pleiotropic effects of type I IFNs. These include:

- **PI3K-AKT pathway**: IFNAR1 activation recruits the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) to the receptor complex, leading to activation of AKT and downstream effectors such as mTOR. This pathway promotes cell survival and protein synthesis and is particularly important for the anti-apoptotic effects of type I IFNs.

- **MAPK pathways**: The p38 MAPK and ERK1/2 pathways are activated downstream of IFNAR1 through mechanisms involving the adaptor proteins VAV and RAC1. These pathways contribute to the pro-inflammatory and growth-inhibitory effects of type I IFNs.

- **CRKL signaling**: The adaptor protein CRKL is phosphorylated in response to IFNAR1 activation and forms a complex with STAT5, contributing to the transcriptional regulation of a subset of ISGs.

- **STING-mediated positive feedback**: The stimulator of interferon genes (STING) protein, which is itself an ISG, participates in a positive feedback loop that amplifies type I IFN production and signaling. STING activation leads to enhanced IFNAR1 signaling, creating a feed-forward mechanism that potentiates the antiviral response.

### 3.3 Regulation of IFNAR1 Signaling

IFNAR1 signaling is subject to multiple layers of negative regulation that prevent excessive or prolonged inflammation and maintain immune homeostasis. The principal regulatory mechanisms include:

**Ubiquitination and proteasomal degradation**: IFNAR1 is constitutively ubiquitinated on lysine residues within its intracellular domain, targeting it for endocytosis and lysosomal/proteasomal degradation. This process is mediated by the E3 ubiquitin ligase SCF(β-TrCP), which recognizes a phosphodegron motif (DSGXXS) in the IFNAR1 ICD. Phosphorylation of this motif by casein kinase 1α (CK1α) and glycogen synthase kinase 3β (GSK3β) is required for β-TrCP binding and subsequent ubiquitination. Inflammatory stimuli, including TNF-α and LPS, can trigger IFNAR1 ubiquitination and downregulation, thereby attenuating type I IFN responses during inflammation. This regulatory mechanism protects tissues from inflammatory injury by limiting the duration and magnitude of IFNAR signaling.

**Suppressor of cytokine signaling (SOCS) proteins**: SOCS1 and SOCS3 are ISGs that function as classical negative feedback inhibitors of JAK-STAT signaling. SOCS1 binds directly to JAK kinases and inhibits their catalytic activity, while SOCS3 competes with STAT proteins for binding to receptor phosphotyrosine motifs. The expression of SOCS1 and SOCS3 is induced by IFNAR1 signaling, creating a negative feedback loop that limits signal duration. During influenza A virus infection, SOCS1 and SOCS3 negatively regulate the innate immune response through a RIG-I/IFNAR1-dependent pathway, modulating the balance between antiviral protection and immunopathology.

**Protein tyrosine phosphatases**: Several protein tyrosine phosphatases, including SHP-1, SHP-2, and PTP1B, dephosphorylate JAKs and STATs, terminating signaling. SHP-1 is constitutively associated with IFNAR1 and is activated upon receptor engagement, providing rapid signal termination.

**Endocytic trafficking**: The retromer complex regulates the spatiotemporal control of IFNAR signaling by sorting internalized receptors for recycling to the plasma membrane or for degradation. Clathrin-dependent endocytosis of IFNAR is required for JAK/STAT signaling, and the retromer complex modulates the duration and intensity of signaling by controlling receptor recycling. Disruption of retromer function alters the balance between recycling and degradation, thereby affecting the magnitude of ISG induction.

**Deubiquitylases**: The BRCC36 isopeptidase complex (BRISC) removes K63-linked polyubiquitin chains from IFNAR1, counteracting the ubiquitination that promotes receptor degradation. BRISC-mediated deubiquitylation stabilizes IFNAR1 at the cell surface and sustains signaling. Small-molecule inhibitors of BRISC deubiquitylase activity have been developed and shown to modulate inflammatory signaling, representing a potential therapeutic strategy for targeting IFNAR1 function.

### 3.4 Protein-Protein Interaction Networks

IFNAR1 participates in an extensive protein-protein interaction network that extends beyond the core JAK-STAT components. The intracellular domain of IFNAR1 interacts with TYK2, STAT1, STAT2, STAT3, and the regulatory subunit of PI3K. Additional interaction partners identified through proteomic screens include:

- **TYK2**: The primary JAK kinase associated with IFNAR1, essential for IFNAR1 phosphorylation and downstream signaling.
- **STING**: Interacts with IFNAR1 to mediate positive feedback regulation of type I IFN signaling.
- **Prolidase (PEPD)**: A cytosolic peptidase that regulates IFNAR1 surface expression by modulating receptor trafficking. Flaviviruses, including encephalitic flaviviruses, antagonize type I IFN signaling by downregulating IFNAR1 through a mechanism involving prolidase, revealing a host factor that is exploited by viruses to evade innate immunity.
- **USP25**: A ubiquitin-specific protease that is induced by the type I IFN-IRF7 axis and may regulate IFNAR1 stability.
- **HDAC3**: Histone deacetylase 3 regulates the inflammatory gene expression program in rheumatoid arthritis fibroblast-like synoviocytes, potentially through effects on IFNAR1 signaling.

```mermaid
sequenceDiagram
    participant L as "Type I IFN (IFN-α/β)"
    participant R2 as "IFNAR2"
    participant R1 as "IFNAR1"
    participant J1 as "JAK1"
    participant T2 as "TYK2"
    participant S1 as "STAT1"
    participant S2 as "STAT2"
    participant I9 as "IRF9"
    participant N as "Nucleus"
    participant ISG as "ISG Transcription"
    L->>R2: High-affinity binding
    R2->>R1: Recruits IFNAR1 (low-affinity)
    R1->>J1: Conformational change
    J1->>T2: Trans-phosphorylation
    T2->>S2: Phosphorylates STAT2 (Tyr690)
    J1->>S1: Phosphorylates STAT1 (Tyr701)
    S1->>S2: Heterodimerization
    S2->>I9: Association with IRF9
    S1->>N: ISGF3 complex translocates
    N->>ISG: Binds ISRE elements
    ISG->>ISG: Upregulation of antiviral effectors
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Inborn Errors of Immunity: IFNAR1 Deficiency

Germline mutations in IFNAR1 cause an inborn error of immunity characterized by increased susceptibility to severe viral infections. The clinical phenotype of IFNAR1 deficiency is highly variable, ranging from life-threatening viral encephalitis to relatively mild or asymptomatic courses, reflecting the influence of genetic background, viral exposure, and environmental factors.

**Glu386* nonsense mutation**: A loss-of-function variant resulting in a premature stop codon at position 386 (Glu386*) has been identified as a relatively common pathogenic allele in certain populations. This mutation truncates the protein within the extracellular domain, eliminating the transmembrane and intracellular domains, and results in complete loss of IFNAR1 function. Individuals homozygous for the Glu386* variant have impaired type I IFN signaling and can suffer severe illness when exposed to certain viruses, including live attenuated vaccines. The Glu386* variant can be detected by tri-allelic genotyping, which distinguishes it from other alleles at the same locus.

**Critical COVID-19 pneumonia and MIS-C**: A child with inherited IFNAR1 deficiency presented with both critical COVID-19 pneumonia and multisystem inflammatory syndrome in children (MIS-C), demonstrating that IFNAR1 deficiency can predispose to severe SARS-CoV-2 infection and its post-infectious complications. This case highlights the dual role of type I IFN signaling in both controlling viral replication and modulating the inflammatory response. The patient's clinical course underscores the importance of IFNAR1 in antiviral defense against SARS-CoV-2 and the potential for IFNAR1 variants to contribute to the spectrum of COVID-19 outcomes.

**Hepatocellular injury**: IFNAR1 deficiency has been associated with hepatocellular injury in some patients, although the mechanisms remain incompletely understood. The liver phenotype may reflect dysregulated immune responses to viral infections or altered hepatocyte-intrinsic IFNAR signaling that affects cellular homeostasis.

### 4.2 Common Polymorphisms and Disease Associations

Several common single nucleotide polymorphisms (SNPs) and structural variants in IFNAR1 have been associated with susceptibility or resistance to various infectious and autoimmune diseases:

**rs17875871 (deletion allele)**: A deletion polymorphism in the IFNAR1 gene has been associated with a lower risk of breast cancer. The deletion allele may alter IFNAR1 expression or function in ways that affect tumor immune surveillance, although the precise mechanism requires further investigation.

**Promoter polymorphisms and multiple sclerosis**: Polymorphisms in the IFNAR1 promoter region have been studied for their association with therapeutic response to interferon-beta in multiple sclerosis (MS) patients. While some studies have suggested that promoter variants influence treatment outcomes, a comprehensive gene expression study of 25 candidate biomarkers, including IFNAR1, denied their ability to predict interferon-beta treatment response in MS patients. The expression level of IFNAR1 in Iranian MS patients treated with IFN-β has also been examined, with variable results.

**HIV infection and AIDS progression**: Exhaustive genotyping of IFNAR1 in a French AIDS cohort identified an IFNAR1 protein variant associated with AIDS progression or susceptibility to HIV-1 infection. Subsequent studies have examined IFNAR1 gene polymorphisms in HIV-infected patients, revealing associations with disease outcomes. Next-generation sequencing of IFNAR1 variants in relation to HIV-1 disease progression and antiretroviral therapy response has provided additional insights into the role of IFNAR1 in HIV pathogenesis.

**Hand, foot, and mouth disease (HFMD)**: A functional polymorphism in IFNAR1 is associated with susceptibility and severity of HFMD with enterovirus 71 (EV71) infection. This finding implicates IFNAR1 variation in the variable clinical manifestations of EV71 infection, which ranges from mild febrile illness to severe neurological complications.

**Hepatitis B and C**: IFNAR1 gene polymorphisms have been associated with chronic hepatitis B virus infection in a Thai population. The IFNA1 (-2C→T) polymorphism is associated with increased IFNAR1 gene expression levels in chronic hepatitis B infection. For hepatitis C, a dinucleotide microsatellite polymorphism in the IFNAR1 gene promoter correlates with responsiveness of patients to interferon therapy. Expression of IFNAR1 and IFNAR2 mRNA in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. Polymorphisms in IFNAR1 have also been studied in patients with chronic hepatitis C receiving combined IFN-alpha therapy.

**Tuberculosis**: A proline deletion in IFNAR1 (delPro168) impairs IFN signaling and underlies increased resistance to tuberculosis in humans. This variant reduces type I IFN signaling, which paradoxically enhances host resistance to Mycobacterium tuberculosis, consistent with the notion that type I IFNs can impair host defense against intracellular bacteria. The IFNAR1 variant also influences gut microbial production of palmitoleic acid and host immune responses to tuberculosis, revealing a complex host-genotype-microbiome-immune axis.

**Cerebral malaria**: IFNAR1 variants are associated with protection against cerebral malaria in The Gambia. Type I interferon receptor variants in gene regulatory regions are also associated with susceptibility to cerebral malaria in Malawi. These findings suggest that modulation of type I IFN signaling influences the risk of severe malaria.

**Developmental stuttering**: A mutation in the IFNAR1 gene may contribute to developmental stuttering in the Chinese population. Whole-exome sequencing identified a potential IFNAR1 variant in affected individuals, although the functional significance and generalizability of this finding require confirmation.

**Ankylosing spondylitis**: IFNAR1 has been identified as a potential biomarker mediated by immune infiltration and osteoclast differentiation in ankylosing spondylitis. The gene is differentially expressed in peripheral blood of patients and may contribute to the inflammatory pathology of this condition.

### 4.3 In Silico Prediction of Deleterious Variants

Computational approaches have been employed to identify deleterious non-synonymous SNPs (nsSNPs) in IFNAR1 that may affect protein function and contribute to disease susceptibility. In silico mutational analysis using multiple prediction algorithms (SIFT, PolyPhen-2, PANTHER, etc.) has identified several nsSNPs predicted to be damaging, including variants that alter protein stability, ligand binding, or protein-protein interactions. These computational predictions provide a framework for prioritizing variants for functional validation and clinical genotyping.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Antagonism of IFNAR1

Given the central role of IFNAR1 in antiviral defense, it is not surprising that numerous viruses have evolved strategies to antagonize IFNAR1 expression, signaling, or function. These viral evasion mechanisms highlight the critical importance of IFNAR1 in the host antiviral response and reveal vulnerabilities that can be exploited for therapeutic intervention.

**[Feline calicivirus](/knowledge/viruses/pet-viruses/feline-calicivirus) (FCV)**: The FCV strain 2280 p30 protein antagonizes type I interferon-mediated antiviral innate immunity through directly degrading IFNAR1 mRNA. This represents a novel mechanism of viral immune evasion, wherein a viral protein directly targets the IFNAR1 transcript for degradation, thereby reducing receptor expression and dampening the cellular response to type I IFNs.

**[African swine fever virus](/knowledge/viruses/livestock-viruses/african-swine-fever-virus) (ASFV)**: The ASFV pB318L protein, a trans-geranylgeranyl-diphosphate synthase, negatively regulates both the cGAS-STING and IFNAR-JAK-STAT signaling pathways. By reducing the expression of IFNAR1 and downstream signaling components, pB318L suppresses the host antiviral response and facilitates viral replication.

**Lumpy skin disease virus (LSDV)**: The LSDV protein LSDV122 impairs IFN-I receptor complex formation to evade host innate immunity. This protein interferes with the assembly of the IFNAR1/IFNAR2 heterodimer, preventing effective type I IFN signaling.

**Flaviviruses**: Encephalitic flaviviruses antagonize type I IFN signaling through a mechanism involving prolidase, a regulator of IFNAR1 surface expression. Viral infection leads to reduced IFNAR1 surface levels, thereby suppressing the cellular response to type I IFNs and promoting viral replication.

**Influenza A virus**: The innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. While this is a host regulatory mechanism, viruses can exploit SOCS-mediated negative feedback to limit the antiviral response.

### 5.2 IFNAR1 Knockout Models for Viral Studies

IFNAR1 knockout (KO) mice and cell lines have become indispensable tools for studying viral pathogenesis and antiviral immunity. The generation of Ifnar1 KO mice using CRISPR/Cas9 technology has streamlined the production of these models. These mice are highly susceptible to a wide range of viral infections, including Zika virus, Japanese encephalitis virus, and influenza virus, making them valuable for vaccine development and antiviral drug testing.

**Zika virus (ZIKV)**: RT-[qPCR analysis](/knowledge/diagnostics/molecular/qpcr-analysis-plate-layout-delta-delta-ct) of inflammatory and apoptotic factor-related gene expression in ZIKV-infected IFNAR1−/− mice has revealed the importance of type I IFN signaling in controlling ZIKV replication and pathogenesis. Dietary selenium and vitamin E deficiency modulate ZIKV pathogenesis and immune response in IFNAR1−/− mice, indicating that nutritional status influences the host-virus interaction.

**Japanese encephalitis virus (JEV)**: Inflammatory and apoptotic factor fluctuations associated with JEV infection in transgenic IFNAR1−/− mice have been characterized, providing insights into the immunopathogenesis of JEV.

**Influenza vaccine production**: Deficiency of IFNAR1 increases the production of influenza vaccine viruses in MDCK cells. Knockout of IFNAR1 in this cell line enhances viral yield by eliminating the antiviral response, thereby improving the efficiency of cell culture-based influenza vaccine production.

**Porcine PK-15 cells**: Generation of porcine PK-15 cells lacking Ifnar1 or Stat2 has been accomplished to optimize the efficiency of viral isolation. These cells are valuable for studying zoonotic viruses that use pigs as intermediate or amplifying hosts.

**Chicken models**: Production of immune receptor knockout chickens via direct in vivo transfection of primordial germ cells has been achieved, including knockout of IFNAR1. These avian models provide unique opportunities for studying host-virus interactions in poultry and for developing disease-resistant breeds.

### 5.3 IFNAR1 in Bacterial and Parasitic Infections

While IFNAR1 is best known for its antiviral functions, type I IFN signaling also modulates immune responses to bacterial and parasitic pathogens. As noted above, a proline deletion in IFNAR1 that impairs IFN signaling is associated with increased resistance to tuberculosis in humans. This finding is consistent with studies in mice showing that type I IFNs can impair host resistance to intracellular bacteria. The IFNAR1 variant also influences the gut microbiome, with effects on palmitoleic acid production that modulate host immune responses to tuberculosis.

In malaria, IFNAR1 variants are associated with protection against cerebral malaria, suggesting that type I IFN signaling contributes to the pathogenesis of severe malaria. The balance between protective and pathogenic effects of type I IFNs in malaria is complex and context-dependent.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Anifrolumab: Anti-IFNAR1 Monoclonal Antibody

The most clinically advanced therapeutic targeting IFNAR1 is **anifrolumab**, a fully human IgG1 kappa monoclonal antibody that binds to IFNAR1 and blocks the signaling of all type I interferons. Anifrolumab was approved by the FDA in 2021 for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) in adults receiving standard therapy.

**Mechanism of action**: Anifrolumab binds to the extracellular domain of IFNAR1 with high affinity, preventing the interaction of type I IFNs with the receptor complex. This blockade inhibits the JAK-STAT signaling pathway and suppresses the expression of interferon-stimulated genes, thereby dampening the type I IFN-driven inflammation that characterizes SLE.

**Clinical efficacy**: In two phase 3 trials (TULIP-1 and TULIP-2), anifrolumab demonstrated significant efficacy in reducing disease activity in SLE patients, particularly in those with a high type I IFN gene signature. Transcriptomic and proteomic analyses of these trials revealed that anifrolumab modulates key immunopathological pathways, including the downregulation of ISGs and the normalization of immune cell subsets. An exploratory analysis of a phase IIb clinical trial showed beneficial effects of anifrolumab on immune cell dysregulation and complement system abnormalities in SLE.

**Additional indications**: Anifrolumab has been investigated for the treatment of systemic sclerosis, where it suppresses T cell activation and collagen accumulation. It has also been studied in cutaneous lupus erythematosus, where it has a direct immunoregulatory effect on inflamed keratinocytes. The drug is being explored in juvenile dermatomyositis, a condition with a prominent type I IFN signature.

**Safety considerations**: Because type I IFN signaling is critical for antiviral defense, anifrolumab treatment is associated with an increased risk of respiratory infections and herpes zoster. Patients receiving anifrolumab should be monitored for infections, and live vaccines should be avoided during treatment.

### 6.2 Other Therapeutic Approaches Targeting IFNAR1

**Anti-IFNAR1 shRNA**: Delivery of anti-IFNAR1 shRNA to hepatic cells decreases IFNAR1 gene expression and improves adenoviral transduction and transgene expression. This approach has potential applications in gene therapy, where transient suppression of IFNAR1 could enhance the efficiency of viral vector-mediated gene delivery.

**IFNAR1 in multiple myeloma**: Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. In multiple myeloma, tumor-derived type I IFNs promote the expansion of regulatory T cells (Tregs), which suppress antitumor immunity. Anti-IFNAR1 antibodies or other inhibitors of IFNAR1 signaling could reverse this immunosuppression and enhance antitumor immune responses.

**IFNAR1 in cancer immunotherapy**: Type I IFN signaling induces melanoma cell-intrinsic PD-1 expression, and inhibition of IFNAR1 antagonizes immune checkpoint blockade. This finding suggests that IFNAR1 signaling can promote immune evasion by upregulating PD-1 on tumor cells, and that combining IFNAR1 inhibition with PD-1 blockade may improve therapeutic outcomes. IFNAR1 downregulation during melanoma progression upregulates αv integrin expression and promotes metastasis, indicating that IFNAR1 loss can drive tumor progression through non-canonical mechanisms.

**IFNAR1 in clear cell renal cell carcinoma**: IFNAR1 has been identified as a key gene regulating immune infiltration in clear cell renal cell carcinoma (ccRCC). An immune escape-related signature has been constructed, and the relationship between IFNAR1 and immune infiltration has been validated by multiple immunohistochemistry. These findings suggest that IFNAR1 expression levels could serve as a biomarker for patient stratification and immunotherapy response prediction in ccRCC.

**IFNAR1 in colorectal cancer**: CLC and IFNAR1 are differentially expressed between early- and late-onset colorectal cancer, and a global immunity score is distinct between these groups. These observations suggest that IFNAR1 expression patterns could inform prognosis and treatment decisions in colorectal cancer.

**IFNAR1 in ankylosing spondylitis**: PLCG2 and IFNAR1 have been identified as potential biomarkers mediated by immune infiltration and osteoclast differentiation in ankylosing spondylitis. Targeting IFNAR1 signaling may represent a therapeutic strategy for this inflammatory rheumatic disease.

### 6.3 Small-Molecule Modulators

While no small-molecule drugs directly targeting IFNAR1 have been approved, several investigational compounds modulate IFNAR1 signaling indirectly:

**BRISC inhibitors**: Molecular glues that inhibit the deubiquitylase activity of the BRCC36 isopeptidase complex (BRISC) have been developed. These compounds stabilize the ubiquitinated form of IFNAR1, promoting its degradation and thereby attenuating type I IFN signaling. Such inhibitors could be useful for treating inflammatory diseases characterized by excessive type I IFN signaling.

**JAK inhibitors**: Although not specific to IFNAR1, JAK inhibitors (e.g., tofacitinib, baricitinib) block the downstream signaling of IFNAR1 and other cytokine receptors. These drugs have been approved for various autoimmune diseases and are being investigated for COVID-19 and other conditions.

**4-Octyl itaconate**: This anti-inflammatory metabolite inhibits cytokine-mediated inflammation via alkylation of TYK2 and JAK1, thereby blocking IFNAR1 signaling. Itaconate derivatives represent a novel class of anti-inflammatory compounds that target the JAK-STAT pathway

## Related Clinical & Scientific Guides

* [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway)
* [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway)
* [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway)